ATNF Profile
180 Life Sciences Corp. is a clinical-stage biotechnology firm focused on developing innovative therapeutics to address significant unmet medical needs in areas such as chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company's research and development efforts are concentrated on several advanced product development platforms.
The company's fibrosis and anti-tumor necrosis factor (anti-TNF) platform is currently in Phase IIb clinical trials, targeting therapeutic solutions for fibrosis and anti-TNF applications. This platform aims to develop treatments that can effectively manage or mitigate the impacts of fibrosis and related conditions.
Another key area of focus for 180 Life Sciences is its Synthetic Cannabidiol (CBD) Analogs platform, which is in the preclinical stage. This platform involves the development of man-made derivatives of CBD, designed to offer therapeutic benefits while potentially improving upon the properties of natural CBD. Additionally, the a7nAChR platform, also in preclinical trials, is centered on the alpha-7 nicotinic acetylcholine receptor. This platform explores immune-suppressive treatments that could provide new approaches for managing immune-related disorders.
Founded in 2016 and headquartered in Palo Alto, California, 180 Life Sciences Corp. is dedicated to advancing its innovative platforms through rigorous research and clinical development. The company's commitment to addressing complex medical challenges positions it at the forefront of biotechnological advancements aimed at improving patient outcomes in chronic and inflammatory conditions.
|
